Kornimate/medical-research-clean huggingface dataset:
prevalence and risk factors of pulmonary hypertension in patients with myeloproliferative neoplasms in assiut university hospital.

Conditions: Myeloproliferative Neoplasm

Summary: this study will evaluate the mpns patients for the presence of ph by using a non invasive method ( transthoracic echocardiography (tte )) and correlate the clinical and laboratory data of these patients with development of ph aiming to identify risk factors for ph and parameters that can predict ph in mpns patients and thus,identifying mpns patients who require close monitoring \& screening for ph ,hoping that early detection and management of ph in mpns patients can improve morbidity, prognosis and survival in those patients.

pulmonary hypertension (ph) is a syndrome characterized by marked remodeling of the pulmonary vasculature and a progressive increase in the pulmonary vascular load. ph is a serious complex disorder that associated with high morbidity and mortality rates. ph is a complication of various hematologic diseases including myeloproliferative neoplasms (mpns) which are included in group 5 ph. myeloproliferative neoplasms (mpns) are a group of diseases characterized by uncontrolled proliferation of at least one myeloid series due to an abnormal hematopoietic cell clone. there are different types of mpns including polycythemia vera (pv), essential thrombocythemia (et), chronic myeloid leukemia (cml), and primary myelofibrosis (pmf). ph is defined as an elevation in the mean pulmonary artery pressure (mpap) that is greater than or equal to 25 mmhg, which was measured at rest via right heart catheterization (rhc). systolic pulmonary artery pressure (spap) can be accurately estimated using doppler transthoracic echocardiography (tte), recent advances in noninvasive imaging led doppler tte to become the most widespread and well-recognized technique for non-invasive spap evaluation and the screening modality of choice for evaluating ph. active monitoring of ph in patients with mpn may be warranted. identification of risk factors predicting ph in mpn patients promises early detection and possibly improved ph management and therapy.

Eligibility criteria:
inclusion criteria: 1. adult patients (≥18 years) 2. patients diagnosed with mpns. including polycythemia vera (pv), essential thrombocythemia (et), chronic myeloid leukemia (cml), and primary myelofibrosis (pmf) exclusion criteria: 1. patients less than 18 years old. 2. patients with cardiac diseases involving the left side of the heart or congenital heart diseases. 3. patients with chronic lung disease and primary pulmonary hypertension. 4. patients with chronic kidney disease. 5. patients with inherited and acquired chronic hemolytic anemia. 6. patients with connective tissue diseases. 7. patients with with past or current pulmonary embolism.

Keywords: pulmonary htn mpns
epidemiological study about the evolution of patients treated for an acute episode of vulvovaginal candidiasis

Conditions: Candidiasis, Vulvovaginal

Summary: to determine proportion of women achieving clinical and mycological cure or have recurrences / reinfection after being treated for an acute episode of vulvovaginal candidiasis.


Eligibility criteria:
inclusion criteria: * sexually active women between 18 and 50 years * patients attending to the gynecologist with acute vulvovaginal candidiasis. * patients requiring standard treatment with clotrimazole 500 single dose and that the decision to prescribe this treatment is prior to inclusion in the study. * women who agree to participate in the study and has signed the informed consent sheet. exclusion criteria: * use of any medication that may interfere significantly with study assessments. * pregnant or breastfeeding * women with signs of other genital infection * within 3 months after childbirth or abortion * patients that is expected not to attend follow-up visits

Keywords: candidiasis
hearttrends heart rate variability (hrv) algorithm for the diagnosis of myocardial ischemia

Conditions: Ischemic Heart Disease

Summary: the investigators intend to prospectively enroll consecutive patients, without known ischemic heart disease, referred by their physician for routine exercise mpi at a tertiary care center. prior to the mpi (nuclear stress test), eligible and consenting patients will undergo a one-hour period of holter ecg digital recording. application of ecg electrodes will be performed by medical technicians following standard recommendations, utilizing approved holter device \& stickers. the holter ecg data will be used for the offline heart rate variability (hrv) analysis by the hearttrends device. immediately following data acquisition, all patients will undergo an exercise mpi according to accepted clinical practice guidelines. following the mpi, there will be no interference with patient management, which will be conducted by the patients' treating physicians according to current guidelines, unaware of hrv results. analysis of recorded ecg data for hrv will be performed blinded to the est and mpi results, by hearttrends device. the results of the hrv tests will not be available to treating physicians and will not be used to guide patient management. patients will be followed for 6 months for the occurrence of coronary interventions and mace, defined as: death, myocardial infarction, unstable angina, or any coronary revascularization.


Eligibility criteria:
inclusion criteria: * age ≥ 21 * referral for exercise mpi by treating physicians * willing and able to provide written informed consent exclusion criteria: * established ischemic heart disease * atrial fibrillation or flutter * acute coronary syndrome * cardiac pacemaker * clinical diagnosis of heart failure * moderate or severe copd * active myocarditis, constrictive pericarditis, any cardiomyopathy, cardiac or systemic amyloidosis * known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or in the opinion of the investigator are not suitable to participate; * any illness that might reduce life expectancy to less than 1 year from screening * left bundle branch block (lbbb), significant intra-ventricular conduction delay (ivcd) or significant (\>1mm) st deviations on baseline ecg * inability to perform an exercise stress test (i.e. orthopedical or neurological limitations) * any significant established myocardial or valvular disease

Keywords: heart rate variability ischemic heart disease myocardial ischemia
physiological changes from hand movement training

Conditions: Stroke

Summary: 11 participants with upper-limb impairment will be recruited from community sources. they will be invited to participate in a 15-day trial involving the iregained device. the study will involve 2 assessment visits to baycrest, before and after the treatment, and 15 treatment visits. the data from the pilot study will be analyzed both quantitatively and qualitatively, as outcomes and explicit feedback from participants will be used to further optimize the device for future studies.

this pilot study will investigate the potential changes in the brain area controlling hand movement following 15 days of exercises to improve hand function in participants with upper limb impairments resulting from stroke. a device developed by dr. vineet johnson (iregained inc.) will be used to administer standardized exercises to improve hand function. to assess brain changes, transcranial magnetic stimulation pulses will be delivered to the motor cortex. the motor evoked potential (mep), a muscle response evoked from the tms, will be measured using electrodes on the hand. this study will test the feasibility of conducting motor therapy using this device while assessing potential changes in motor cortex function. findings from this study will contribute to developing treatment trials aimed at improving impaired limb function in stroke patients and quality of life in these individuals

Eligibility criteria:
inclusion criteria: -sustained a single stroke \>6months prior to start of study exclusion criteria: * severe spasticity or contractures (2 or less in the cmsa) * any other musculoskeletal or neuromuscular disorders that compromise sensation * prospective participants who are incapable of providing consent to participate in the research study will also be excluded (determined by an mmse score of 24 or less). * botox injections less than 2 months prior to starting the study
spinal cord stimulation for neuropathic pain relief : efficacy study using the specific npsi questionnaire (npsi)

Conditions: Neuropathic Pain

Summary: several studies have shown the efficacy of spinal cord stimulation in reducing the intensity of neuropathic pain. this efficacy is defined as obtaining relief of at least 50% of the preoperative pain intensity assessed by the visual analog scale or the digital pain scale. no study has evaluated the efficacy of stimulation specifically on the different components of neuropathic pain, only an overall improvement in pain has been described. a specific questionnaire for neuropathic pain has been extensively validated in neuropathic pain: the neuropathic pain symptom inventory (npsi). thanks to the multidimensional structure of this questionnaire, investigators propose to evaluate separately and in a much more specific way the efficacy of spinal cord stimulation in the short and long term on the different components of neuropathic pain and to define responders subgroups.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * with neuropathic pain: * confirmed (dn4 score\> 4/10) * going back to one year at least * refractory to well-conducted medical treatments * requiring spinal cord stimulation: the indication is validated by the multidisciplinary meeting (rcp neuromodulation / pain at foch hospital) * having given his non-opposition exclusion criteria: * patient with sepsis * having no well-conducted prior medical treatment * with uncontrolled psychiatric disorders (active psychosis, suicidal disorders, severe depression) * with somatoform disorders * addicted to alcohol or drugs or withdrawal syndrome * deprived of liberty or under guardianship.

Keywords: neuropathic pain npsi spinal cord stimulation
evolution of memory related activity

Conditions: Alzheimer's Disease; Mild Cognitive Impairment

Summary: the purpose of this study is to begin the process of validating fmri (functional magnetic resonance imaging) as a biomarker for use in clinical trials and longitudinal studies of clinical progression in mild cognitive impairment (mci) and alzheimer's disease (ad).

the development of biomarkers is now especially critical, as there are a number of promising disease-modifying therapies entering early phase clinical trials, with additional novel therapeutic strategies in development. it is essential to develop biomarkers that can detect a "signal of efficacy" over a relatively short time frame for use in phase ii trials. ideally biomarkers are needed that can reliably detect the earliest brain alterations due to ad pathology, perhaps at a point when there is synaptic dysfunction but not yet widespread neuronal loss. functional neuroimaging, in particular functional mri (fmri), has significant potential, having already shown promise in detecting regionally specific pharmacological effects on memory related neural activity, and as a sensitive marker of very early cognitive impairment. this study, a parallel ancillary study of the alzheimer's disease neuroimaging initiative (adni), will first examine reproducibility of fmri activation, using a face-name associative memory paradigm, and then the alterations in memory-related activation that occur over the course of mci and mild ad. the study will also examine the relationship of fmri activation to clinical variables, memory task performance, genotype, and other imaging techniques cross-sectionally and longitudinally, sampling at multiple time points over a 3-year period.

Eligibility criteria:
inclusion criteria: * ages 55-90 * general good health or stable medical problems * study partner/caregiver able to provide an independent evaluation of the participant's daily functioning * no contraindications to mr scanning * modified hachinski ischemic score ≤4 * geriatric depression scale ≤10 exclusion criteria: * diagnosis of parkinson's disease or other neurological illness * presence of clinically significant/uncontrolled medical conditions * history of stroke, brain tumor, brain surgery, seizures, significant head trauma with loss of consciousness, depression or other psychiatric illness, alcohol or drug abuse in the past 2 years * significant uncorrectable visual impairment

Keywords: functional magnetic resonance imaging
combined antiinflammatory and angiostatic therapy in patients with hormone-refractory prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to evaluate the efficacy, tolerability and safety of a multi-targeted therapy in patients with hormone-refractory prostate cancer.


Eligibility criteria:
inclusion criteria: * histologically confirmed prostate carcinoma, which has proven progression after primary hormone therapy (surgical or medicinal castration). * patients must have increasing psa levels (within 3 months prior to enrollment) with at least two consecutively increasing psa levels. * psa value before inclusion must be at least 5 ng/ml * at least 18 years of age. * at least capable of self care and up of at least 50% of waking hours (ecog performance status 0 - 2), adequate bone marrow function and lab results. exclusion criteria: * change of hormone therapy within 6 weeks prior inclusion * prior chemotherapy * therapy with imatinib, or therapy with other inhibitors of tyrosinkinase. * second neoplasm diagnosed within 5 years before study start. * patients who require therapy with warfarin * known diagnosis of hiv, hepatitis b, or hepatitis c infection. * severe, unstable, or uncontrolled medical disease which would confound diagnoses or evaluations required by the protocol, including severe cardiac insufficiency * surgical therapy within 4 weeks before inclusion. * prior therapy with isotopes strontium or rhenium. * radiation therapy to \> 25% of bone marrow within 4 weeks before inclusion. * treatment with other experimental substances within 30 days before study start. other protocol-defined inclusion/exclusion criteria may apply

Keywords: hormone-refractory prostate cancer multitargeted tyrosinkinase
an algorithm for prognosis of upper limb paresis in patients with subacute stroke

Conditions: Stroke; Upper Limb Hypertonia; Physical Activity

Summary: aim study 1:assess the accuracy of prep2 when applied in a subacute rehabilitation setting. aim study 2: prediction of real life ul use. method: a prospective cohort study. main outcome measure study 1: action research arm test (arat), measuring ul motor function. main outcome study 2: use ratio between affected and unaffected ul measured by accellerometer. secondary outcome measure: fugl-meyer motor assessment for ul (fm).

background accurate prediction of recovery of ul function after stroke can lead to targeted rehabilitation. the predict recovery potential (prep2) algorithm combines individual prediction of ul function with recommendations for treatment. the prep2 algorithm is based on clinical assessment of ul paresis combined with transcranial magnetic stimulation (tms) to examine corticospinal tract integrity. for this phd project the prep2 is modified to be applicable in a rehabilitation setting and the initial assessment of prep2, the safe score, is carried out at day 14. study 1 aim: assess the accuracy of prep2 when applied in a subacute rehabilitation setting. hypothesis: prep2 applied at day 14 post stroke accurately predicts ul function 3 months after stroke for a minimum of 75 % of the patients. method: a prospective cohort study. setting and population: the study will take place at hammel neurorehabilitation centre and university research clinic. ninety patients will be included. inclusion criteria: first or recurrent ischemic or hemorrhagic stroke (diagnosis verified by ct or mr scan); new upper limp impairment; less than 15 days post stroke; ≥ 18 years; able to follow simple commands and cooperate with examinations main outcome measure: action research arm test (arat), measuring ul motor function. secondary outcome measure: fugl-meyer motor and sensory assessment for ul. functional independence measure (fim). examined at baseline: pain wil be assessed with a verbal rating scale. inferior subluxation in the glenohumoral joint. neglect will be assessed with star cancellation test and line bisection test study 2 prediction of real life ul use hypothesis: prep2 can be used to predict real life ul use 3 months post stroke. patients: the entire cohort from study 1 will be included. real life use will be assessed with accelerometers at 3 months follow up. main outcome: is the use ratio between affected and unaffected ul.

Eligibility criteria:
inclusion criteria: * first or recurrent ischemic or hemorrhagic stroke (diagnosis verified by ct or mr scan) * new upper limp impairment; less than 15 days post stroke * ≥ 18 years * able to follow simple commands and cooperate with examinations exclusion criteria: * subarachnoid hemorrhages * ul motor residuals from former stroke * severe illness with life expectancy \< 6 months * place of residence more than 1½ hours drive away and not reachable for follow up assessments * patients with contraindications for tms are excluded from the tms part of the study.
effect of sugammadex for reversal of rocuronium-induced neuromuscular block on perioperative management of awake craniotomy

Conditions: Brain Tumors

Summary: effect of sugammadex for reversal of rocuronium-induced neuromuscular block on perioperative management of awake craniotomy


Eligibility criteria:
inclusion criteria: * age: 18-45 years old body mass index (bmi)≥ 18.5-23.9 kg/m2, asa grade i \~ii. exclusion criteria: * suffering from a mental illness or preoperative communication disorder, patients with claustrophobia, breathing, circulation, neuromuscular system and kidney, and other important viscera function disorder, pregnant or lactating women, a history of malignant hyperthermia, the history of drug allergy in the process of general anesthesia and recent may not used to the interaction between rocuronium, vecuronium bromide reacts drugs (such as aminoglycoside antibiotics, anticonvulsant, magnesium).

Keywords: sugammadex、awake craniotomy
a phase 2 study to evaluate early bactericidal activity, safety, tolerability, and pharmacokinetics of multiple oral doses of telacebec (q203)

Conditions: Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB

Summary: this is a phase iia, open-label, randomized study in treatment-naïve, sputum smear-positive patients with drug-sensitive pulmonary tb to assess the early bactericidal activity of telacebec (q203).


Eligibility criteria:
inclusion criteria: 1. a new episode of pulmonary tb determined by testing at the study appointed laboratory: mycobacterium tuberculosis positive and rifampicin and isoniazid sensitive on a rapid molecular test 2. a chest x-ray taken no more than 14 days before screening which in the opinion of the investigator is consistent with tb 3. sputum smear positive on direct microscopy for acid-fast bacilli on at least 1 pre-treatment sputum sample 4. ability to produce an adequate volume of sputum as determined by an approximately 16-hour overnight sample collection 5. be of non-childbearing potential or using effective methods of birth control, as defined in the protocol exclusion criteria: 1. the patient is mentally or legally incapacitated at screening 2. any condition or circumstance, in the opinion of the investigator, which may make the patient unlikely to complete the study or comply with study procedures and requirements, or may pose a risk to the patient's safety 3. clinically significant evidence of extra-thoracic tb (miliary tb, abdominal tb, urogenital tb, osteoarthritic tb, tb meningitis), as judged by the investigator 4. the patient has been infected with hepatitis b or c virus as confirmed by tests for hepatitis b core antibodies, hepatitis b surface antigens, and the hepatitis c virus antibodies 5. the patient with history of allergic reaction to isoniazid, rifampicin, pyrazinamide, ethambutol or related substances (eg, tosylate), as confirmed by the clinical judgement of the investigator
pre-arrival instructions effect on bystander cardiopulmonary resuscitation (cpr).

Conditions: Heart Arrest; Cardiac Arrest; Cardiopulmonary Arrest; Out of Hospital Cardiac Arrest; Sudden Cardiac Death

Summary: the investigators hypothesized that pre-arrival instructions would increase the likelihood of bystanders performing cardiopulmonary resuscitation (cpr).

the city of milwaukee and surrounding communities combine to form milwaukee county covering 241 square miles and serving approximately 959,521 people. milwaukee county includes 19 separate municipalities. community demographics and other characteristics have remained largely stable for the past decade. the study will take place in milwaukee county from 2009 - 2013 in the communities providing cardiopulmonary resuscitation (cpr) pre-arrival instructions: west allis and oak creek. in milwaukee county basic live support (bls) shall be started on all patients in cardiac arrest with the exception of victims with: decapitation; rigor mortis; evidence of tissue decomposition; dependent lividity; presence of a valid do-not-resuscitate (dnr) or physician orders for life-sustaining treatment (polst); fire victim with full thickness burns to 90% or greater body surface area; hypothermic patients with signs of frozen tissue, rigid airway, ice formation in mouth, or chest noncompliant for cardiopulmonary resuscitation (cpr). the system standard is: cardiopulmonary resuscitation (cpr) will be provided whenever patient is pulseless; compressions at least 100/minute; hands on chest more than 75% of time; minimum compression depth of 2 inches in adults 75% of the time. therefore, the investigators will analyze data to assess how cardiopulmonary resuscitation (cpr) pre-arrival instructions may have affected the probability of receiving bystander cardiopulmonary resuscitation (cpr).

Eligibility criteria:
inclusion criteria: * patients 21 years old or older * presumed cardiac origin as indicated on the milwaukee county emergency medical services (mcems) report * non-emergency medical services (ems) witnessed arrest exclusion criteria: * patients younger than 21 years old * patients who are "obviously dead" (decomposition, rigor mortis, decapitation, or other) * trauma victims, including hanging and burns * patients with cardiac arrests clearly of other non-cardiac origin including drug overdose, carbon monoxide poisoning, drowning, exsanguination, electrocution, asphyxia, hypoxia related to respiratory disease, cerebrovascular accident and documented terminal illness * patients determined to be a do-not-resuscitate (dnr) upon arrival of emergency medical services (ems) providers * cardiopulmonary resuscitation (cpr) by someone other than emergency medical services (ems) who is a trained first responder or health care provider with a predetermined duty to provide care.

Keywords: prehospital emergency care out of hospital cardiac arrest cardiopulmonary resuscitation cpr heart arrest outcome bystander